Understand the 2020 health care directory adjustment focus! 7 big ticket companies how to make the most of it.

Wen . . . On the evening of August 3rd, a number of government officials from foreign enterprises stayed up all night, interpreting the scheme in the middle of the night and thinking about the access path in the middle of the night.
Looking forward to, the 2020 National Health Insurance Drug Catalog Adjustment Work Programme (Draft for Comments) was finally released on August 3rd, according to the last National Health Insurance Administration issued the Health Insurance Drug Catalog Adjustment Work Programme has been 17 and a half months, this is also the "Basic Health Insurance Drug Administration Interim Measures" after the official release of a major landing initiative, the dynamic adjustment of the health insurance catalog, in principle, once a year.
The guiding ideology of the national medical reform is the main thrust of the national medical security bureau as China's medical security system to deepen the front-line, carrying enormous challenges and pressures, after the bright work in 2019, this year to start the 2020 health insurance directory adjustment, this carrying significance will be different from 2019.
To interpret the "target tasks" in the work programme from the three "key tasks": 1. Increase: from "establishing and improving a more equitable and sustainable health care system" to "continuously deepening the reform of the health care system and establishing a dynamic adjustment mechanism for the drug catalogue", to some extent inheriting the positive experience of the reform of the health care security system since 2019, in order to continue to deepen as an opportunity.
2. Changes: From "appropriate expansion of the scope of the catalogue in accordance with the Fund's ability to pay" to "dynamic adjustment of the scope of the drug catalogue in accordance with the Fund's ability to pay" also reflects that this adjustment is different from the previous health insurance directory adjustment "expansion", this "dynamic adjustment" indicates that the appropriate continued transfer of new drugs necessary for clinical use, the removal of unsuitable drugs, there is progress, may be a wide range of out will also become characteristic.
work programme has also placed greater emphasis on making payments more efficient and efficient, ensuring greater fair access, emphasizing the utility of payments and ensuring fairness and accessability.
3. The fundamental objectives range from "further improving the level of basic medical insurance drug security and alleviating the high cost of drug use" to "promoting the modernization of the medical insurance drug governance system and governance capacity, and helping to solve the people's worries about seeking medical treatment".
Pay more attention to the scientific nature of the governance system of medical insurance drugs, the advanced nature of governance capacity, and from the solution of drug difficulties, expensive basic use needs, to fundamentally solve the fundamental interests of the people, the worries appear more humane.
million people focus on the scope of the directory adjustment of the Health Insurance Bureau this time the health insurance directory adjustment is obviously more experienced, more confident, more clear objectives, the health insurance directory adjustment work programme is a bright spot is to give a direct under card - adjustment scope, compared to the 2019 adjustment of the relatively broad text description, does reflect its ability to promote the health insurance drug governance system and governance.
And the scope of this adjustment is based on the following three considerations: 1. Functional positioning of the national medical insurance drug catalog function positioning clear, to solve the people's worries about medical treatment, all adjustment work will be to maintain the people's health this interest point.
2. The clinical needs of medicines include truly clinically necessary, precise efficacy, and safe drugs in the catalogue, continuing to confirm the scientific opinion of experts on the basis of highlighting clinical needs in 2019.
3. The fund's affordability from the drug catalogue into and out of the need to take into account the fund's affordability, the use of the fund is larger, the clinical use of unreasonable drugs will certainly not be able to enter the catalogue.
The State Health Insurance Administration shall issue seven categories of medical insurance catalogue tickets to Western medicines and traditional Chinese medicines outside the catalogue, please take a seat on the number: the prerequisites need to comply with the provisions of Articles 7 and 8 of the Interim Measures for the Administration of Drug Use in Basic Medical Insurance, and drugs outside the catalogue with one of the following circumstances may be included in the scope of new drugs to be added to the drug catalogue in 2020.
of the drug is: this kind of drug meets the basic conditions of clinical necessity, safety and effectiveness, reasonable price and so on.
this time it will take a lot of clinical experts to show their hand.
seven categories of tickets are not suitable, the utility of enterprises are not the same.
first of all, (1), (2), (4) article has little impact on enterprises, itself new coronary pneumonia-related drug health insurance payment timely, medical insurance reimbursement to give full support, but also as this year's health insurance bureau anti-epidemic work a bright spot.
2018 edition of the Essential Medicines Catalog will determine its value and status in the 2019 edition of the HealthCare."
and the collection varieties themselves are in the health insurance directory.
(3), (5), (6), (7) is of great value to the enterprise and deserves in-depth study.
second, the value to different enterprises is also different.
innovative pharmaceutical companies pay more attention to 5, 6, innovative drugs and new adaptations approved, especially some foreign enterprises CDE approval of new adaptations, in addition to access, the scope of payment needs to be determined.
the domestic pharmaceutical enterprises are more focused on 7, into more than 5 local health insurance provinces catalog varieties, to a certain extent to give enterprises vitality, to the national pharmaceutical enterprises in a sense of support.
addition, speed up cage-for-bird, for local health insurance catalog access products, do not have to wait three years 442 ratio out, this year completed once.
(1) medication for respiratory diseases related to new coronary pneumonia.
3, there were more than 17.91 million confirmed cases of new coronary pneumonia worldwide, and the disease is likely to persist, according to WHO.
In 2020, the National Health Insurance Administration will spend 1,232 million on diseases related to new coronary pneumonia, and it is imperative to make health insurance payments for new coronary pneumonia-related diseases, but the modification of "respiratory diseases" has nothing to do with the treatment of diseases caused by secondary injuries of new coronary pneumonia and the payment of health insurance.
(2) are included in the National Essential Medicines Catalog (2018 edition).
19th edition of the health insurance catalogue has begun to cover essential medicines, in a sense enhancing the value of the essential medicines catalogue.
essential medicines catalogue is positioned in the general sense of WHO to protect the patient's basic drug needs, so entering the essential medicines catalogue is equivalent to buying a pre-sale ticket for a "medicare catalogue".
(3) to be included in the list of new drugs in urgent clinical need abroad, to encourage generic drug catalogs, or to encourage research and development of declared children's medicines, and to be approved for market by the State Drug Administration by December 31, 2019.
to meet CDE approvals in 2019 to encourage the urgent need for new drugs, encourage generics, and encourage children to take drugs, a scope that further emphasizes the functional positioning of the health insurance catalog.
(4) the second batch of state-organized drug centralized procurement of selected drugs.
is the first time that the national medical insurance catalogue has been linked to the centralized procurement of drugs by state organizations, which is of a certain significance to strengthen the value of selected drugs in the centralized procurement of medicines by national organizations.
(5) Between January 1, 2015 and December 31, 2019, drugs (including new active ingredients, new dosage forms) approved for market by the State Drug Administration in accordance with the new drug registration application process.
: approval to go public, only approved listing can get this round of review tickets.
(6) Between January 1, 2015 and December 31, 2019, additional applications and approvals were made to the State Drug Administration based on the results of clinical trials, and drugs with significant changes in adaptive disorders, functional management, etc.
Keywords: Approved, this part of the time limit is December 31, 2019, which means that applications that are outside this time range or that have not been approved will not be included in this healthcare review and will be retried next year.
(7) By December 31, 2019, enter more than 5 of the latest provincial health insurance drug catalogs.
, the main active ingredients were included in the "first batch of national key monitoring of rational drug catalogue" except.
The seventh category of tickets is the most valuable, to a certain extent in the context of deepening the reform of the health care system, the balance between centralization and division of power, but also to a certain extent to recognize the value and efforts of local health insurance review, I believe that most domestic pharmaceutical companies after a 442 ratio of withdrawal from the local health insurance directory, this will be a once-in-a-lifetime opportunity.
still maintain the results of medical reform, for the Health And Health Commission issued the "first batch of national key monitoring of rational drug drug catalog" to give affirmation, with the catalog of varieties are not considered.
and traditional Chinese medicines outside the catalogue of eligible drugs shall be declared by enterprises in accordance with the procedures and shall be included in the proposed new scope after examination and approval.
focus: enterprises need to submit applications, in accordance with the procedures for review, and enterprises ready to submit materials will be crucial, as strong as possible to explain that the products meet the scope of access, but also to fully prove that in line with clinical requirements, safe and effective, reasonable price elements.
2020 program continues to consolidate the results of the reform of the health care system1. Process optimization, focusing on the 2019 drug catalog adjustment is divided into preparation, review, release of regular access catalog, negotiation, release of negotiation access catalog 5 stages.
2020 drug catalog adjustment is divided into five stages: preparation, enterprise declaration, expert review, negotiation and bidding, publication of results, 2020 is more simplified and focused, increase the enterprise declaration and negotiation bidding process.
2. Enterprise declaration reflects the progress of medical insurance review published enterprise declaration guidelines.
to adjust the scope of the 2020 drug catalog, and accept eligible enterprises to submit the necessary information to the National Health Insurance Center as required.
information should be reviewed in a formal manner and medicines examined in the form of a formal examination should be made public.
The form of enterprise declaration is mentioned in the Interim Measures for the Administration of Basic Medical Insurance Drugs, which is also the experience of exchanges with foreign medical reimbursement agencies in that year, and the transparency and openness of medical insurance evaluation is more reflected in the publicity of drugs, which is an important progress in this medical insurance evaluation.
and bidding will further consolidate the results of the reform of the health care system The National Health Insurance Agency shall organize negotiations or access bids by experts in the fields of pharmaceutical economics and health insurance management, as required.
exclusive drugs into the negotiation process, non-exclusive drugs into the enterprise access auction link.
is also a bright spot in this health-care directory adjustment.
the need for enterprises to assess and measure, access to health insurance or self-funded, good or bad? This reform will lead to all kinds of health insurance will enter the price-to-price link, the health insurance fund will benefit more, fundamentally solve the people's worries about medical treatment.
anyway, the 2020 health-care directory adjustment will start, as the 2019 health-care directory adjustment will bring us too much surprise and joy, which may be what mediters have to bear on the road to reform.
from the beginning of "focusing on building a more equitable and sustainable health care system" to "promoting the modernization of medicare drug governance systems and governance capabilities," the "super-health insurance bureau" took only a year.
quality, or speed, let us realize that health care reform into the deep water area, the power of change is huge.
And in the 2020 health care directory adjustment work programme, the guiding ideology, the scope of adjustment, and the work process will be the focus of our research, this part of our relationship with the country, the fundamental interests of patients, whether we can qualify and ensure that every step of the way must win.
medicine will eventually return to its roots and be used to cure patients.
to the end of the 2020 health care directory, with only five months left and few days left.
: Some of the varieties that Insight has compiled that may enter into health insurance or participate in negotiations are for industry reference only.
domestic drug part, where no new approved adaptations are counted.
the imported drug part, where no new approved allergies are counted.
.